Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

919
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
919
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

577
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
577
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carbohydrate antigen 125: promising diagnostic biomarker in heart failure with preserved ejection fraction.

Heart (British Cardiac Society)·2025
Same author

Macrophage migration inhibitory factor (MIF): can functional insights pave the way for future therapeutics in cardiovascular diseases?

Expert opinion on therapeutic targets·2025
Same author

Multifactorial management of complex comorbidity followed by heart failure, chronic kidney disease and type 2 diabetes mellitus: the way to overcome missed opportunities.

Heart (British Cardiac Society)·2025
Same author

Missed Opportunities in Implementation and Optimization of Lipid-Lowering Therapies in Very-High-Risk Patients Presenting with ST-Segment Elevation Myocardial Infarction.

Journal of clinical medicine·2023
Same author

Early beta-blocker therapy improves in-hospital mortality of patients with non-ST-segment elevation myocardial infarction - a meta-analysis.

International journal of cardiology·2023
Same author

Myocardial Mechanical Dispersion Predicts Adverse Cardiac Remodeling in Patients with ST Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2023

Related Experiment Video

Updated: Mar 25, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.1K

Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients?

Alexander Berezin1

  • 1Internal Medicine Department, State Medical University, 26, Mayakovsky Av., Zaporozhye, Postcode 69035, Ukraine.

Diabetes & Metabolic Syndrome
|February 13, 2016
PubMed
Summary
This summary is machine-generated.

Fetuin-A and osteoprotegerin (OPG) are key biomarkers for cardiovascular risk in type 2 diabetes mellitus (T2DM). Their decreased levels during treatment need further investigation regarding cardiovascular protection.

Keywords:
BiomarkersCardiovascular diseaseDiabetes mellitusOsteoprotegerinVascular calcification

More Related Videos

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis
02:08

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis

Published on: July 5, 2024

1.6K
Preparation of Naringenin Solution for In Vivo Application
08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

3.9K

Related Experiment Videos

Last Updated: Mar 25, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.1K
Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis
02:08

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis

Published on: July 5, 2024

1.6K
Preparation of Naringenin Solution for In Vivo Application
08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

3.9K

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Research
  • Diabetes Mellitus Research

Background:

  • Fetuin-A and osteoprotegerin (OPG) are established biomarkers associated with atherosclerosis, vascular calcification, and inflammation in type 2 diabetes mellitus (T2DM).
  • These biomarkers have demonstrated potential in cardiovascular risk stratification among T2DM patients.
  • Existing research suggests a potential protective role for fetuin-A and OPG against cardiovascular complications.

Discussion:

  • The clinical significance of reduced serum concentrations of fetuin-A and OPG during T2DM treatment with thiazolidinediones (e.g., pioglitazone) and metformin remains unclear.
  • Investigating the impact of these drug-induced changes in biomarker levels on cardiovascular risk is crucial.
  • Understanding these relationships can refine therapeutic strategies for T2DM patients.

Key Insights:

  • Fetuin-A and OPG are linked to cardiovascular health in T2DM.
  • Decreased levels of these biomarkers during specific diabetes treatments warrant further study.
  • The protective mechanisms of fetuin-A and OPG in T2DM require elucidation.

Outlook:

  • Further research is needed to clarify the relationship between thiazolidinedione/metformin-induced changes in fetuin-A and OPG levels and subsequent cardiovascular risk.
  • Clinical trials could explore the therapeutic modulation of these biomarkers for improved cardiovascular outcomes in T2DM.
  • Longitudinal studies are essential to track the long-term effects of these medications on fetuin-A, OPG, and cardiovascular events.